China’s Zhifei Biological Links Up With GSK on Shingles Shots

(Bloomberg) — GSK Plc clinched a partnership with Chinese vaccine maker Chongqing Zhifei Biological Products Co. to boost sales in China of its blockbuster shingles immunization.

Under the agreement, GSK will sell £2.5 billion ($3 billion) of its Shingrix shot to Zhifei over three years. The Chinese company, which already distributes Merck & Co.’s Gardasil, will promote the shot across 30,000 vaccination points to spur uptake, GSK said Monday in a statement.